Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
veterinary vaccine (FMD)
- Development stage
- Preclinical
- Lead developer
- Quratis
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
The veterinary vaccine (FMD) is a preclinical-stage vaccine candidate being developed by Quratis, a South Korean biopharmaceutical company. The vaccine is designed to protect livestock, such as cattle, pigs, sheep, and goats, against Foot and Mouth Disease (FMD), a highly contagious viral disease caused by the Foot and Mouth Disease Virus (FMDV). Developed in collaboration with partners like Optipharm, the vaccine utilizes recombinant protein antigen technology to stimulate a protective immune response against FMDV. It is currently in preclinical development.
- Other names
- FMD veterinary vaccineFoot and Mouth Disease veterinary vaccine구제역 백신
Beyond the preview
Go deeper on veterinary vaccine (FMD).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on veterinary vaccine (FMD).